Latest Breaking News On - Christina cameron - Page 1 : comparemela.com

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesChristina cameronSuperkine immunotherapiesPembrolizumab keytrudaMerck sharp dohmeSafety review committeeMerck co incOncology innovation forumMedicenna therapeutics corpDurable single agent activityPotent immune effector responseDose escalation portionAnnual oncology innovationAnnual oncology innovation forumFahar merchantOrphan drug

Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting

Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesChristina cameronSuperkine immunotherapiesAmerican society of clinical oncologyWhile the companyProgram committeeScientific program committeeMerck sharp dohmeMerck co incMedicenna therapeutics corpProvides updateAmerican societyClinical oncologyDose escalation studyEngineered long actingAmerican association

Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management

Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 Medicenna Therapeutics Corp. , a clinical-stage.

United statesChristina cameronSuperkine immunotherapiesMedicenna therapeutics corpRa capital healthcare fundHealthcare fundPre funded warrantsUnited states securities actOrphan drugTargeted metalloprotease activated superkineAnnual reportMedia contact

Medicenna Therapeutics Announces CA$20 Million Investment

Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024 .

United statesSuperkine immunotherapiesChristina cameronMedicenna therapeutics corpRa capital healthcare fundHealthcare fundFahar merchantPre funded warrantsUnited states securities actOrphan drugTargeted metalloprotease activated superkineAnnual reportMedia contactToronto stock exchange mdnaMedicenna therapeutics corp

Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting

Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Duke universityNorth carolinaUnited statesWestern australiaSuperkine immunotherapiesJohn sampsonChristina cameronSchool of medicineMedicenna therapeutics corpUniversity of queenslandMerck co incGallipoli medical research foundationMerck sharp dohmeAnnounces oral presentationMedicenna therapeuticsAnnual meeting